- Home
- MDV vs PROK Comparison
MDV vs PROK Comparison
Compare MDV & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDV
- PROK
- Stock Information
- Founded
- MDV 2015
- PROK 2015
- Country
- MDV United States
- PROK United States
- Employees
- MDV N/A
- PROK N/A
- Industry
- MDV Transportation Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDV Consumer Discretionary
- PROK Health Care
- Exchange
- MDV Nasdaq
- PROK Nasdaq
- Market Cap
- MDV 152.5M
- PROK 126.8M
- IPO Year
- MDV 2022
- PROK N/A
- Fundamental
- Price
- MDV $16.04
- PROK $0.91
- Analyst Decision
- MDV Strong Buy
- PROK Buy
- Analyst Count
- MDV 1
- PROK 4
- Target Price
- MDV $18.00
- PROK $5.00
- AVG Volume (30 Days)
- MDV 45.1K
- PROK 479.2K
- Earning Date
- MDV 03-04-2025
- PROK 03-17-2025
- Dividend Yield
- MDV 7.27%
- PROK N/A
- EPS Growth
- MDV N/A
- PROK N/A
- EPS
- MDV 0.25
- PROK N/A
- Revenue
- MDV $46,907,000.00
- PROK $76,000.00
- Revenue This Year
- MDV $1.68
- PROK N/A
- Revenue Next Year
- MDV $7.49
- PROK N/A
- P/E Ratio
- MDV $63.62
- PROK N/A
- Revenue Growth
- MDV N/A
- PROK N/A
- 52 Week Low
- MDV $13.69
- PROK $0.86
- 52 Week High
- MDV $18.11
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- MDV 57.45
- PROK 31.60
- Support Level
- MDV $15.56
- PROK $0.87
- Resistance Level
- MDV $16.07
- PROK $1.06
- Average True Range (ATR)
- MDV 0.58
- PROK 0.10
- MACD
- MDV 0.02
- PROK 0.01
- Stochastic Oscillator
- MDV 82.38
- PROK 18.75
About MDV Modiv Industrial Inc. Class C
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.